Prescription medications and breast cancer : how do bisphosphonates and omeprazole affect a woman’s risk of developing breast cancer?
department or school: Medicine, Faculty of
department or school: Population and Public Health (SPPH), School of
data provider: DSpace
degree campus: UBCV
creator: Bakos, Brendan
issued: 2019-04-10T15:57:26Z
issued: 2019
related degree: Master of Science - MSc
degree grantor: University of British Columbia
description: Background: Breast cancer is the most commonly diagnosed cancer in women. It is a heterogeneous disease having a number of risk factors that vary by menopausal status and disease subtype. There is evidence that some pharmaceutical medications may affect breast cancer risk. This thesis investigated bisphosphonates, which are used to treat osteoporosis, as well as omeprazole, a proton pump inhibitor used to treat gastroesophageal reflux disease, and their association with breast cancer and breast cancer subtypes. Methods: This study utilized questionnaire information provided by participants in the Canadian Breast Cancer Study, a case-control study conducted jointly in Vancouver, British Columbia and Kingston, Ontario. Data from the British Columbia arm of the study was linked to PharmaNet, an administrative pharmaceutical database that records prescriptions dispensed in British Columbia. Multiple imputation and logistic regression were used to model the association between the prescription medications and breast cancer while adjusting for confounders. Results: There was not enough evidence to suggest an association between omeprazole and breast cancer, considered either as a whole (OR: 1.02; 95% CI: 0.68-1.52) or by estrogen receptor status (p-heterogeneity = 0.94). However, there was evidence to suggest long-term bisphosphonate use (>1025 cumulative Defined Daily Doses) was associated with a decreased risk of invasive breast cancer, relative to no bisphosphonate use (OR: 0.65; 95% CI: 0.45-0.94). The protective effect was not evident for situ disease (OR: 0.89; 95% CI: 0.36-2.19). There was no difference in risk observed by estrogen receptor status (p-heterogeneity = 0.83). Conclusions: This research showed a protective effect for invasive breast cancer with long-term bisphosphonate use, but the results must be interpreted cautiously due to the potential for confounding by indication. This potential bias has been mitigated somewhat by adjusting for factors strongly …
aggregated CHO: https://circle.library.ubc.ca/rest/handle/2429/69558
note: Prescription medications and breast cancer: how do bisphosphonates and omeprazole affect a woman’s risk of developing breast cancer? by Brendan Bakos B.Sc. (Hons), University of Calgary, 2011 A THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF MASTER OF SCIENCE in THE FACULTY OF GRADUATE AND POSTDOCTORAL STUDIES (Population and Public Health) THE UNIVERSITY OF BRITISH COLUMBIA (Vancouver) April 2019 © Brendan Bakos, 2019 ii The following individuals certify that they have read, and recommend to the Faculty of Graduate and Postdoctoral Studies for acceptance, a thesis/dissertation entitled: Prescription medications and breast cancer: how do bisphosphonates and omeprazole affect a woman’s risk of developing breast cancer? submitted by Brendan Bakos in partial fulfillment of the requirements for the degree of Master of Science in Population and Public Health Examining Committee: Dr. John Spinelli, School of Population and Public Health Supervisor Dr. Trevor Dummer, School of Population and Public Health Supervisory Committee Member Dr. Dean Regier, School of Population and Public Health Additional Examiner Additional Supervisory Committee Members: Dr. Rachel Murphy, School of Population and Public Health iii Abstract Background: Breast cancer is the most commonly diagnosed cancer in women. It is a heterogeneous disease having a number of risk factors that vary by menopausal status and disease subtype. There is evidence that some pharmaceutical medications may affect breast cancer risk. This thesis investigated bisphosphonates, which are used to treat osteoporosis, as well as omeprazole, a proton pump inhibitor used to treat gastroesophageal reflux disease, and their association with breast cancer and breast cancer subtypes. Methods: This study utilized questionnaire information provided by participants in the Canadian Breast Cancer Study, a case-control study conducted jointly in Vancouver, British Columbia and Kingston, Ontario. Data from t…
has type: Thesis/Dissertation
date issued: 2019-05
is shown at: 10.14288/1.0378077
language: eng
degree discipline: Population and Public Health
provider: Vancouver : University of British Columbia Library
publisher: University of British Columbia
rights: Attribution-NonCommercial-NoDerivatives 4.0 International
rights URI: http://creativecommons.org/licenses/by-nc-nd/4.0/
scholar level: Graduate
type: Text
identifier URI: http://hdl.handle.net/2429/69558